SCHEMBL1269717

SCHEMBL1269717

COC(=O)c1nc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Sc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ LMNA P02545 4/20 0.44
▸ GAA P10253 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ CNR1 P21554 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ NOD2 Q9HC29 1/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268953 0.92 ALDH1A1 (0.45) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269539 0.91 KMT2A (0.43) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269360 0.89 KMT2A (0.44) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269706 0.89 ALDH1A1 (0.42) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1268682 0.89 KMT2A (0.43) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269715 0.88 MEN1 (0.43) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269670 0.86 KMT2A (0.42) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL1269909 0.84 TP53 (0.42) MEN1KMT2ALMNAGAAHSD17B10
SCHEMBL1268515 0.83 ALDH1A1 (0.41) MEN1KMT2ALMNAALDH1A1HSD17B10
SCHEMBL1269783 0.83 ALDH1A1 (0.41) MEN1KMT2ALMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885LMNA 2576/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885LMNA 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback